Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2007-10-23
2007-10-23
Yaen, Christopher H. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
Reexamination Certificate
active
10182033
ABSTRACT:
The present invention concerns compositions and methods for the treatment of disorders characterized by the over-expression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
REFERENCES:
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5693465 (1997-12-01), Manning et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 6649342 (2003-11-01), Mack et al.
patent: 6750013 (2004-06-01), Gish et al.
patent: 6762020 (2004-07-01), Mack et al.
patent: 6780586 (2004-08-01), Mack et al.
patent: 2002/0006616 (2002-01-01), Gish et al.
patent: 2004/0141983 (2004-07-01), Law et al.
patent: 2132500 (1996-03-01), None
patent: 19813839 (1999-09-01), None
patent: 474727 (1997-07-01), None
patent: 1033401 (2000-09-01), None
patent: PCT/US 89/00051 (1989-01-01), None
patent: WO 89/06692 (1989-07-01), None
patent: PCT/US 90/02697 (1990-05-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO 96/27011 (1996-09-01), None
patent: PCT/US 97/18385 (1997-10-01), None
patent: WO 98/17797 (1998-04-01), None
patent: WO 98/50555 (1998-11-01), None
patent: PCT/US 98/26266 (1998-12-01), None
patent: PCT/US 99/06673 (1999-03-01), None
patent: WO 99/31140 (1999-06-01), None
patent: WO 99/48527 (1999-09-01), None
patent: WO 2000/22130 (2000-04-01), None
patent: 00/55629 (2000-09-01), None
patent: WO 2000/55174 (2000-09-01), None
patent: WO 2000/58336 (2000-10-01), None
patent: WO 2000/60076 (2000-10-01), None
patent: WO 2001/18022 (2001-03-01), None
patent: WO02/16939 (2002-02-01), None
patent: WO02/059377 (2002-08-01), None
patent: 2004/067564 (2004-08-01), None
Altschul and Gish, “Local Alignment Statistics”Methods in Enzymology266:460-480 (1996).
Altschul et al., “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs”Nucleic Acids Research. 25(17):3389-3402 (1997).
Blattner, F.R. et al., “The Complete Genome Sequence ofEscherichia coliK-12”EMBL Database(Acc. No. AE000299; XP-002175108) (Jan. 29, 1997).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (May 1992).
Dehesh, K., “Cuphea Hookeriana Thioesterase FatB1-1 mRNA, complete cds”EMBL Database(Acc. No. AFO62400; XP-002175109) (Nov. 12, 1998).
El-Tanani, M.K.K. and C.D. Green, “Interaction Between Estradiol and cAMP in the Regulation of Specific Gene Expression”Mol.&Cellular Endocrinology124(1-2):71-77 (1996).
El-Tanani, Mohammed K.K. and C.D. Green, “Interaction Between Estradiol and Growth Factors in the Regulation of Specific Gene Expression in MCF-7 Human Breast Cancer Cells,”Journal of Steroid Biochem. and Mol. Bio.60(5-6):269-276 (1997).
Fendly, B.M. et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product”Cancer Research50:1550-1558 (Mar. 1, 1990).
Freund, Y.R. and Blair, P.B., “Depression of Natural Killer Activity and Mitogen Responsiveness in Mice Treated with Pristane”J. Immunol.129:2826-2830 (1982).
Green, C. et al., “Homo sapiensEstrogen Regulated LIV-1 Protein (LIV-1) mRNA, complete cds”NCBI Database(Acc. No. U41060, Version 2; GI: 12711792) (XP002175107 Feb. 8, 2001).
Green, C. et al., “Human Breast Cancer, Estrogen Regulated LIV-1 Protein (LIV-1) mRNA, partial cds”NCBI Database(Acc. No. U41060, version 1; GI: 1256000) (XP002175106 Apr. 6, 1996).
Hattori, M. et al., “Homo sapiensgenomic DNA, chromosome 18q12 clone: RP11-701C9, Working Draft Sequence, 15 unordered pieces”EMBL Database(Acc. No. AP001158) (Feb. 15, 2000).
Hongo, J.S. et al., “Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β1”Hybridoma14:253-260 (1995).
Jones et al., “Replacing the Complentarity-Determining Regions in a Human Antibody with Those From a Mouse.”Nature. 321:522-525 (May 29, 1986).
Knowlden, J.M. et al., “Use of Reverse Transcription-Polymerase Chain Reaction Methodology to Detect Estrogen-regulated Gene Expression in Small Breast Cancer Specimens”Clin. Cancer Res.3(11):2165-2172 (1997).
Kohler and Milstein., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity.”Nature. 256:495-497 (Aug. 7, 1975).
Kononen, J. et al., “Tissue microarrays for high-throughput molecular profiling of tumor specimens”Nature Medicine4:844-847 (1998).
Lu and Gillett., “An Optimized Protocol for In Situ Hybridization Using PCR-Generated 33P-Labeled Riboprobes.”Cell Vision. 1(2):169-176 (1994).
Manning, D.L. et al., “Differential Expression of Oestrogen Regulated Genes in Breast Cancer”Acta Oncologica34(5):641-646 (1995).
Manning, D.L. et al., “Oestrogen-regulated Genes in Breast Cancer: Association of pLIV1 With Lymph Node Involvement”European J. Cancer30A(5): 675-678 (1994).
Manning, D.L. et al., “The Role of Four Oestrogen-responsive Genes, pLIV1, pS2, pSYD3 and pSYD8, in Predicting Reponsiveness to Endocrine Therapy in Primary Breast Cancer”European J. Cancer29A(10):1462-1468 (1993).
McClelland, R.A. et al., “Effects of short-tern antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on extrogen-regulated genes”Breast Cancer Res. and Treatment41(1):31-41 (1996).
McClelland, R.A. et al., “Oestrogen-regulated genes in breast cancer: associated of pLIV1 with response to endocrine therapy”British J. Cancer77(10):1653-1656 (1998).
Nakamura, G.R. et al., “Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1”Journal of Virology67(10):6179-6191 (Oct. 1993).
Renz, M.E. et al., “Structural requirements for adhesion of soluble recombinant murine vascular cell adhesion molecule-1 to α4β1”Journal of Cell Biology125(6):1395-1406 (Jun. 1994).
Riechmann et al., “Reshaping Human Antibodies for Therapy”Nature332:323-327 (Mar. 24, 1988).
Taylor, K.M. et al., “LIV-1 Breast Cancer Protein Belongs to a New Family of Histidine-rich Transmembrane Proteins with Potential to Control Intracellular Zn++”Clinical&Experimental Metastasis(XP-001013451) 17(9):758 (1999).
Taylor, K.M. et al., “The LIV-1 Gene, Implicated in Metastatic Breast Cancer, Codes for a Histidine-rich Transmembrane Protein”British Journal of Cancer(XP001013344) 80(Supp. 2) :pp. 24 (Jul. 1999).
Taylor, K.M., “LIV-1 Breast Cancer Protein Belongs to New Family of Histidine-rich Membrane Proteins with Potential to Control Intracellular Zn++ Homeostas”IUBMB Life49(4):249-253 (Apr. 2000).
Verhoeyen et al. “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”Science239:1534-1536 (Mar. 25, 1988).
de Sauvage Frederic
Goddard Audrey
Gurney Austin L.
Hongo Jo-Anne S.
Smith Victoria
Conley Dierdre L.
Dreger Ginger R.
Genentech Inc.
Heller Ehrman LLP
Yaen Christopher H.
LandOfFree
Compositions and methods for treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3846304